Search research articles
Contact Us
Filters
Showing results (141-150 of 170) with videos related to
Page
of 17
Sort By:
Leukemia & Lymphoma
|
September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
Hemasphere
|
January 12, 2026
Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations
Stella Charalampopoulou, Silvia Ramos-Campoy, Marti Duran-Ferrer, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Cancer Research
|
February 4, 2010
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
Verònica Fernàndez, Olga Salamero, Blanca Espinet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Oncotarget
|
November 9, 2016
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Gonzalo Blanco, Anna Puiggros, Panagiotis Baliakas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood Advances
|
November 29, 2021
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
Moraima Jiménez, Elisa Roldán, Candela Fernández-Naval, et al.
Plos One
|
December 3, 2015
A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia
José Ángel Hernández, María Hernández-Sánchez, Ana Eugenia Rodríguez-Vicente, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 170) with videos related to
Sort By:
Page
of 17
Leukemia & Lymphoma
|
September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
Hemasphere
|
January 12, 2026
Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations
Stella Charalampopoulou, Silvia Ramos-Campoy, Marti Duran-Ferrer, et al.
Oncotarget
|
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I Gordon, Reem Karmali, Jason B Kaplan, et al.
Cancer Research
|
February 4, 2010
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
Verònica Fernàndez, Olga Salamero, Blanca Espinet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 27, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Oncotarget
|
November 9, 2016
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Gonzalo Blanco, Anna Puiggros, Panagiotis Baliakas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2025
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Blood Advances
|
November 29, 2021
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
Moraima Jiménez, Elisa Roldán, Candela Fernández-Naval, et al.
Plos One
|
December 3, 2015
A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia
José Ángel Hernández, María Hernández-Sánchez, Ana Eugenia Rodríguez-Vicente, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
Page
of 17